New Releases from NCBI BookshelfAcalabrutinib (Calquence): Indication: Acalabrutinib in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant: Reimbursement Recommendation [Internet].Acalabrutinib (Calquence): Indication: Acalabrutinib in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Calquence should be reimbursed by public drug plans for the treatment of adult patients […]
